Of the 20 trial participants, only two patients to-date have received an initial dosing, which took place in December
2022 (refer ASX release 7 December 2022).
All of the data prepared in this release are from a total of two patients. I have not attained a PhD in biostatistics (please chip in if you have), but a barely-commenced clinical study where n=2 is a curious basis for a 5 page press release from a public company.
The 'Disclosure Committee' want to show off how well their trial is going, for obvious reasons. Not convinced disclosures like this will restore investor confidence or sp.
- Forums
- ASX - By Stock
- Ann: Halucenex Phase II Clinical Trial Update
Of the 20 trial participants, only two patients to-date have...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online